LGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorption (2024)

References

  1. Kong, Y.Y. et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397, 315–323 (1999).

    CAS Google Scholar

  2. Hanada, R., Hanada, T., Sigl, V., Schramek, D. & Penninger, J.M. RANKL/RANK-beyond bones. J. Mol. Med. 89, 647–656 (2011).

    CAS PubMed Google Scholar

  3. Fata, J.E. et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 103, 41–50 (2000).

    CAS PubMed Google Scholar

  4. Jones, D.H. et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440, 692–696 (2006).

    CAS PubMed Google Scholar

  5. Gonzalez-Suarez, E. et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 468, 103–107 (2010).

    CAS PubMed Google Scholar

  6. Tan, W. et al. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 470, 548–553 (2011).

    CAS PubMed PubMed Central Google Scholar

  7. Schramek, D. et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 468, 98–102 (2010).

    CAS PubMed PubMed Central Google Scholar

  8. Kiechl, S. et al. Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat. Med. 19, 358–363 (2013).

    CAS PubMed Google Scholar

  9. Hanada, R. et al. Central control of fever and female body temperature by RANKL/RANK. Nature 462, 505–509 (2009).

    CAS PubMed Google Scholar

  10. Simonet, W.S. et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89, 309–319 (1997).

    CAS PubMed Google Scholar

  11. Lacey, D.L. et al. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat. Rev. Drug Discov. 11, 401–419 (2012).

    CAS PubMed Google Scholar

  12. Weng, J. et al. Deletion of G protein-coupled receptor 48 leads to ocular anterior segment dysgenesis (ASD) through down-regulation of Pitx2. Proc. Natl. Acad. Sci. USA 105, 6081–6086 (2008).

    CAS PubMed Google Scholar

  13. Luo, J. et al. Regulation of bone formation and remodeling by G-protein-coupled receptor 48. Development 136, 2747–2756 (2009).

    CAS PubMed PubMed Central Google Scholar

  14. Carmon, K.S., Gong, X., Lin, Q., Thomas, A. & Liu, Q. R-spondins function as ligands of the orphan receptors LGR4 and LGR5 to regulate Wnt/beta-catenin signaling. Proc. Natl. Acad. Sci. USA 108, 11452–11457 (2011).

    CAS PubMed Google Scholar

  15. de Lau, W. et al. Lgr5 hom*ologues associate with Wnt receptors and mediate R-spondin signalling. Nature 476, 293–297 (2011).

    CAS PubMed Google Scholar

  16. Styrkarsdottir, U. et al. Nonsense mutation in the LGR4 gene is associated with several human diseases and other traits. Nature 497, 517–520 (2013).

    CAS PubMed Google Scholar

  17. Abe, E. et al. TSH is a negative regulator of skeletal remodeling. Cell 115, 151–162 (2003).

    CAS PubMed Google Scholar

  18. Sun, L. et al. FSH directly regulates bone mass. Cell 125, 247–260 (2006).

    CAS PubMed Google Scholar

  19. Du, B. et al. Lgr4/Gpr48 negatively regulates TLR2/4-associated pattern recognition and innate immunity by targeting CD14 expression. J. Biol. Chem. 288, 15131–15141 (2013).

    CAS PubMed PubMed Central Google Scholar

  20. Wang, Y. et al. Lgr4 regulates mammary gland development and stem cell activity through the pluripotency transcription factor Sox2. Stem Cells 31, 1921–1931 (2013).

    CAS PubMed PubMed Central Google Scholar

  21. Wang, J. et al. Ablation of LGR4 promotes energy expenditure by driving white-to-brown fat switch. Nat. Cell Biol. 15, 1455–1463 (2013).

    CAS PubMed Google Scholar

  22. Gao, Y. et al. Up-regulation of GPR48 induced by down-regulation of p27Kip1 enhances carcinoma cell invasiveness and metastasis. Cancer Res. 66, 11623–11631 (2006).

    CAS PubMed Google Scholar

  23. Wu, J. et al. GPR48, a poor prognostic factor, promotes tumor metastasis and activates β-catenin/TCF signaling in colorectal cancer. Carcinogenesis 34, 2861–2869 (2013).

    CAS PubMed Google Scholar

  24. Joshi, P.A. et al. RANK signaling amplifies WNT-responsive mammary progenitors through R-SPONDIN1. Stem Cell Reports 5, 31–44 (2015).

    CAS PubMed PubMed Central Google Scholar

  25. Wang, D. et al. Structural basis for R-spondin recognition by LGR4/5/6 receptors. Genes Dev. 27, 1339–1344 (2013).

    CAS PubMed PubMed Central Google Scholar

  26. Deng, C. et al. Multi-functional norrin is a ligand for the LGR4 receptor. J. Cell Sci. 126, 2060–2068 (2013).

    CAS PubMed PubMed Central Google Scholar

  27. Tang, X. et al. GPR116, an adhesion G-protein-coupled receptor, promotes breast cancer metastasis via the Gαq-p63RhoGEF-Rho GTPase pathway. Cancer Res. 73, 6206–6218 (2013).

    CAS PubMed Google Scholar

  28. Clapham, D.E. Calcium signaling. Cell 131, 1047–1058 (2007).

    CAS Google Scholar

  29. Wu, X. et al. RANKL regulates Fas expression and Fas-mediated apoptosis in osteoclasts. J. Bone Miner. Res. 20, 107–116 (2005).

    CAS PubMed Google Scholar

  30. Krönke, G. et al. R-spondin 1 protects against inflammatory bone damage during murine arthritis by modulating the Wnt pathway. Arthritis Rheum. 62, 2303–2312 (2010).

    PubMed Google Scholar

  31. Moon, J.B. et al. Akt induces osteoclast differentiation through regulating the GSK3β/NFATc1 signaling cascade. J. Immunol. 188, 163–169 (2012).

    CAS PubMed Google Scholar

  32. Takesh*ta, S. et al. Osteoclast-secreted CTHRC1 in the coupling of bone resorption to formation. J. Clin. Invest. 123, 3914–3924 (2013).

    CAS PubMed PubMed Central Google Scholar

  33. Mizuno, A. et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem. Biophys. Res. Commun. 247, 610–615 (1998).

    CAS PubMed Google Scholar

  34. Lacey, D.L. et al. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am. J. Pathol. 157, 435–448 (2000).

    CAS PubMed PubMed Central Google Scholar

  35. Jimi, E. et al. Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function. J. Immunol. 163, 434–442 (1999).

    CAS PubMed Google Scholar

  36. Boyce, B.F. Advances in the regulation of osteoclasts and osteoclast functions. J. Dent. Res. 92, 860–867 (2013).

    CAS PubMed PubMed Central Google Scholar

  37. Manolagas, S.C. & Parfitt, A.M. What old means to bone. Trends Endocrinol. Metab. 21, 369–374 (2010).

    CAS PubMed PubMed Central Google Scholar

  38. Pierce, B.G., Hourai, Y. & Weng, Z. Accelerating protein docking in ZDOCK using an advanced 3D convolution library. PLoS One 6, e24657 (2011).

    CAS PubMed PubMed Central Google Scholar

  39. Dai, W. et al. Improvement in low-hom*ology template-based modeling by employing a model evaluation method with focus on topology. PLoS One 9, e89935 (2014).

    PubMed PubMed Central Google Scholar

  40. Li, C. et al. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways. J. Bone Miner. Res. 26, 644–656 (2011).

    CAS PubMed Google Scholar

  41. Chu, G.C. et al. RANK- and c-Met-mediated signal network promotes prostate cancer metastatic colonization. Endocr. Relat. Cancer 21, 311–326 (2014).

    CAS PubMed PubMed Central Google Scholar

  42. Wu, X. et al. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways. J. Bone Miner. Res. 27, 1298–1308 (2012).

    CAS PubMed Google Scholar

  43. McMichael, B.K., Meyer, S.M. & Lee, B.S. c-Src-mediated phosphorylation of thyroid hormone receptor-interacting protein 6 (TRIP6) promotes osteoclast sealing zone formation. J. Biol. Chem. 285, 26641–26651 (2010).

    CAS PubMed PubMed Central Google Scholar

  44. Zhang, Z. et al. Ferroportin1 deficiency in mouse macrophages impairs iron homeostasis and inflammatory responses. Blood 118, 1912–1922 (2011).

    CAS PubMed Google Scholar

Download references

LGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorption (2024)

References

Top Articles
Latest Posts
Article information

Author: Msgr. Refugio Daniel

Last Updated:

Views: 6567

Rating: 4.3 / 5 (54 voted)

Reviews: 93% of readers found this page helpful

Author information

Name: Msgr. Refugio Daniel

Birthday: 1999-09-15

Address: 8416 Beatty Center, Derekfort, VA 72092-0500

Phone: +6838967160603

Job: Mining Executive

Hobby: Woodworking, Knitting, Fishing, Coffee roasting, Kayaking, Horseback riding, Kite flying

Introduction: My name is Msgr. Refugio Daniel, I am a fine, precious, encouraging, calm, glamorous, vivacious, friendly person who loves writing and wants to share my knowledge and understanding with you.